Alzheimer Disease, Blood Brain Barrier, Cognitive Dysfunction, Dementia
Conditions
Brief summary
This study attempts to replicate the findings published in Nature Medicine by Nation and colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals, individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction is investigated. The integrity of the blood-brain barrier is investigated by using a novel MRI protocol as well as a novel biomarker in the cerebrospinal fluid.
Interventions
DIAGNOSTIC_TESTContrast agent enhanced MRI using Gadovist
By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
Sponsors
Prof. Dr. med. Jochen Fiebach (Senior Physician)
Charite University, Berlin, Germany
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
\- ≥ 50 years with neuropsychologically confirmed no cognitive dysfunction, mild cognitive impairment or mild dementia Exclusion cirteria: * no current or prior history of any neurological or psychiatric condition, which might affect cognitive function * no neurodegenerative disease other than AD * specifically no extensive vascular white matter dementia or vascular dementia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Marker of blood-brain dysfunction using MRI | 1 day | Dynamic T1 contrast enhanced sequence using Gadovist |
| Markers of blood-brain dysfunction using CSF | 1 day | Platelet-derived growth factor receptor-β in CSF |
Countries
Germany
Outcome results
None listed